Literature DB >> 17982305

Higher prevalence of cardiovascular events among patients with abnormal atrial depolarization and coronary artery disease at 18 months' post-exercise tolerance testing.

David H Spodick1, Vignendra Ariyarajah, Sirin Apiyasawat.   

Abstract

Abnormal atrial depolarization, denoted as interatrial block (IAB; P wave >110 ms), is associated with myocardial ischemia during exercise. The authors conducted an 18-month follow-up for cardiovascular events in 31 consecutive patients with IAB and 60 controls without IAB at rest; participants had coronary artery disease and hypertension and had undergone coronary angiography following positive exercise tolerance test (ETT) results. Atrial fibrillation and need for repeat ETT and coronary artery revascularization were significant with IAB (77.4% vs 20%; P<.001). In patients with such events, IAB, left atrial dilatation, left ventricular hypertrophy, increased left ventricular end-diastolic volume, poorer Duke prognostic treadmill (DPT) scores, and significant coronary artery stenoses were predominant. IAB (hazard ratio [HR], 4.9; 95% confidence interval [CI], 1.3-19.7; P=.02) and DPT scores (HR, 0.84; 95% CI, 0.72-0.98; P=.03) were independently associated with these events. At 18 months' follow-up, IAB at rest was associated with cardiovascular events among those with known coronary artery disease and hypertension.

Entities:  

Mesh:

Year:  2007        PMID: 17982305     DOI: 10.1111/j.1541-9215.2007.07361.x

Source DB:  PubMed          Journal:  Am Heart Hosp J        ISSN: 1541-9215


  2 in total

Review 1.  P-wave dispersion: an update.

Authors:  Andrés Ricardo Pérez-Riera; Luiz Carlos de Abreu; Raimundo Barbosa-Barros; José Grindler; Acácio Fernandes-Cardoso; Adrian Baranchuk
Journal:  Indian Pacing Electrophysiol J       Date:  2016-10-20

Review 2.  The Vectorcardiogram and the Main Dromotropic Disturbances.

Authors:  Andrés R Pérez-Riera; Raimundo Barbosa-Barros; Rodrigo Daminello-Raimundo; Luiz C de Abreu; Kjell Nikus
Journal:  Curr Cardiol Rev       Date:  2021
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.